Quality of Life, Emotional Status, and Adherence of HIV-1–Infected Patients Treated With Efavirenz Versus Protease Inhibitor–Containing Regimens-Reference-Cited by-同舟云学术

Quality of Life, Emotional Status, and Adherence of HIV-1–Infected Patients Treated With Efavirenz Versus Protease Inhibitor–Containing Regimens

Published:2002-03 Issue:3 Volume:29 Page:244-253
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes

Author:

Fumaz Carmina R.,Tuldrà Albert,Ferrer Ma José,Paredes Roger,Bonjoch Anna,Jou Toni,Negredo Eugènia,Romeu Joan,Sirera Guillem,Tural Cristina,Clotet Bonaventura

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference30 articles.

1. Developing and evaluating cross-cultural instruments from minimum requirements to optimal models

2. Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection

3. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection

4. Monitoring Adherence to HIV Therapy

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiretroviral drugs from multiple classes induce loss of excitatory synapses between hippocampal neurons in culture;Frontiers in Pharmacology;2024-03-12

2. Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial;Medicine;2023-11-03

3. Analysis of TPH-2 single nucleotide polymorphisms and depressive symptoms in a Mexican cohort of HIV-1 patients treated with efavirenz- and atazanavir;2023-09-22

4. Biotransformation of Efavirenz and Proteomic Analysis of Cytochrome P450s and UDP-Glucuronosyltransferases in Mouse, Macaque, and Human Brain-Derived In Vitro Systems;Drug Metabolism and Disposition;2023-01-09

5. Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice;Drug Design, Development and Therapy;2022-06